BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 35590394)

  • 1. The importance of N6-methyladenosine modification in tumor immunity and immunotherapy.
    Zhang Z; Liu F; Chen W; Liao Z; Zhang W; Zhang B; Liang H; Chu L; Zhang Z
    Exp Hematol Oncol; 2022 May; 11(1):30. PubMed ID: 35590394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N6-Methyladenosine RNA Modification in the Tumor Immune Microenvironment: Novel Implications for Immunotherapy.
    Guo L; Yang H; Zhou C; Shi Y; Huang L; Zhang J
    Front Immunol; 2021; 12():773570. PubMed ID: 34956201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roles and therapeutic implications of m6A modification in cancer immunotherapy.
    Pan J; Huang T; Deng Z; Zou C
    Front Immunol; 2023; 14():1132601. PubMed ID: 36960074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive Analysis of N6-methyladenosine Modification Patterns Associated With Multiomic Characteristics of Bladder Cancer.
    Liu J; Wang J; Wu M; Zhang W; Meng L; Wang J; Lv Z; Xia H; Zhang Y; Wang J
    Front Med (Lausanne); 2021; 8():757432. PubMed ID: 35004726
    [No Abstract]   [Full Text] [Related]  

  • 5. RNA Modification of N6-Methyladenosine Predicts Immune Phenotypes and Therapeutic Opportunities in Kidney Renal Clear Cell Carcinoma.
    Li H; Hu J; Yu A; Othmane B; Guo T; Liu J; Cheng C; Chen J; Zu X
    Front Oncol; 2021; 11():642159. PubMed ID: 33816290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N6-methyladenosine Regulator-Mediated Immune Genes Identify Breast Cancer Immune Subtypes and Predict Immunotherapy Efficacy.
    Zhang MM; Lin YL; Zeng WF; Li Y; Yang Y; Liu M; Ye YJ; Jiang KW; Wang S; Wang S
    Front Genet; 2021; 12():790888. PubMed ID: 34976022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N6-methyladenosine modification participates in neoplastic immunoregulation and tumorigenesis.
    Zhao W; Li J; Ma Q; Cai J; Li A; Wu W; Lv Y; Cai M
    J Cell Physiol; 2022 Jul; 237(7):2729-2739. PubMed ID: 35342948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Manipulating the tumour immune microenvironment by N6-methyladenosine RNA modification.
    Sun X; Wang H; Pu X; Wu Y; Yuan X; Wang X; Lu H
    Cancer Gene Ther; 2024 Jun; ():. PubMed ID: 38834772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N6-Methyladenosine Modification Patterns and Tumor Microenvironment Immune Characteristics Associated With Clinical Prognosis Analysis in Stomach Adenocarcinoma.
    Meijing Z; Tianhang L; Biao Y
    Front Cell Dev Biol; 2022; 10():913307. PubMed ID: 35813200
    [No Abstract]   [Full Text] [Related]  

  • 10. Crosstalk between N6-methyladenosine (m6A) modification and noncoding RNA in tumor microenvironment.
    Wang D; Han Y; Peng L; Huang T; He X; Wang J; Ou C
    Int J Biol Sci; 2023; 19(7):2198-2219. PubMed ID: 37151887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of N6-Methyladenosine Modification Patterns and Tumor Immune Microenvironment in Pancreatic Adenocarcinoma.
    Liu Y; Li G; Yang Y; Lu Z; Wang T; Wang X; Liu J
    Front Genet; 2021; 12():752025. PubMed ID: 35046996
    [No Abstract]   [Full Text] [Related]  

  • 12. Insights into N6-methyladenosine (m6A) modification of noncoding RNA in tumor microenvironment.
    Zhang Y; Zhan L; Li J; Jiang X; Yin L
    Aging (Albany NY); 2023 May; 15(9):3857-3889. PubMed ID: 37178254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N6-methyladenosine (m6A)-mediated messenger RNA signatures and the tumor immune microenvironment can predict the prognosis of hepatocellular carcinoma.
    Shen S; Yan J; Zhang Y; Dong Z; Xing J; He Y
    Ann Transl Med; 2021 Jan; 9(1):59. PubMed ID: 33553352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One Stone, Two Birds: N6-Methyladenosine RNA Modification in Leukemia Stem Cells and the Tumor Immune Microenvironment in Acute Myeloid Leukemia.
    Ouyang X; Gong Y
    Front Immunol; 2022; 13():912526. PubMed ID: 35720276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N6-Methyladenosine Modification Participates in the Progression of Hepatitis B Virus-Related Liver Fibrosis by Regulating Immune Cell Infiltration.
    Zhao T; Qi J; Liu T; Wu H; Zhu Q
    Front Med (Lausanne); 2022; 9():821710. PubMed ID: 35308519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N6-Methyladenosine Modification Opens a New Chapter in Circular RNA Biology.
    Wu J; Guo X; Wen Y; Huang S; Yuan X; Tang L; Sun H
    Front Cell Dev Biol; 2021; 9():709299. PubMed ID: 34368159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N6-Methyladenosine-Sculpted Regulatory Landscape of Noncoding RNA.
    Zhang Z; Wei W; Wang H; Dong J
    Front Oncol; 2021; 11():743990. PubMed ID: 34722298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. m6A Regulator-Associated Modification Patterns and Immune Infiltration of the Tumor Microenvironment in Hepatocarcinoma.
    Li J; Wang W; Zhou Y; Liu L; Zhang G; Guan K; Cui X; Liu X; Huang M; Cui G; Sun R
    Front Cell Dev Biol; 2021; 9():687756. PubMed ID: 34277630
    [No Abstract]   [Full Text] [Related]  

  • 19. RNA N6-methyladenosine (m6A) modification in HNSCC: molecular mechanism and therapeutic potential.
    Sun X; Fu S; Yuan X; Pu X; Wang R; Wang X; Lu H
    Cancer Gene Ther; 2023 Sep; 30(9):1209-1214. PubMed ID: 37221404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N6-Methyladenosine Regulator-Mediated Immue Patterns and Tumor Microenvironment Infiltration Characterization in Glioblastoma.
    Xiong W; Li C; Wan B; Zheng Z; Zhang Y; Wang S; Fan J
    Front Immunol; 2022; 13():819080. PubMed ID: 35359993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.